1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy210.1169
Abstract: Abstract Background When β-lactam antibiotics are administered intravenously, a significant portion of each dose can be excreted through the bile into the intestine. This excess antibiotic disrupts the balance of the gut microbiome making the… read more here.
Keywords: ribaxamase; antimicrobial resistance; emergence antimicrobial; syn 004 ... See more keywords
The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies
Sign Up to like & getrecommendations! Published in 2017 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02197-16
Abstract: ABSTRACT SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam antibiotic that is excreted… read more here.
Keywords: clinical studies; ribaxamase; 004 ribaxamase; syn 004 ... See more keywords